Current efforts and interventions to curb AMR
According to the Global Burden of Disease study, bacterial infections cause around 37 million deaths globally, making AMR among dangerous bacteria a significant health problem (Murray et al., 2022). The 68th World Health Assembly created and accepted the Global Action Plan on AMR (GAP–AMR) in 2015 after receiving support from several international organizations (World Health, 2024b). The AMR Political Declaration adopted by the 71st UN General Assembly in 2016 affirmed the GAP-AMR and its five strategic objectives as the blueprint for addressing AMR globally and has informed the development of National Action Plans (NAPs). By the end of 2023, 178 countries had developed NAPs based on this framework with 68% implementing their plans, 25% having costed and budgeted NAPs and with Monitoring & Evaluation frameworks. However, so far only 10% of countries have responded that they have made specific financial provisions for implementing their NAPs which highlights the cross-cutting nature of AMR interventions.) (Gupta and Bhatia, 2023). In India, the 12th (2012-2017) five-year plan included the National Program on AMR Containment, which was started in 2013 and is managed by the National Centre for Disease Control (NCDC). The National Antimicrobial Resistance Surveillance Network (NARS-Net) was gradually extended to all states and Union Territories (UTs). (Figure 3) illustrates priority pathogens monitored under NARS - Net. Because of this effort, by March 2024, the program had 50 medical colleges and labs in 27 states and 6 UTs, guaranteeing geographic representation. After certification, “WHONET” an offline, open-source program for managing microbiological data, is used by the NCDC to evaluate surveillance data from NARS-Net sentinel sites. The 5-year NAP-AMR (2017–2021) was a crucial foundation for states to create action plans to address AMR locally because India’s healthcare system is state-governed (Nair et al., 2021). Similarly, ICMR created an AMR monitoring network (AMRSN) to gather nationally representative data on the trends and patterns of antibiotic resistance in pathogens of public health significance.
Figure. List of priority pathogens included under national antimicrobial resistance surveillance network (NARS-Net India). (See the original article for the figure.)
Precision medicine
Current treatment practices can be boiled down to a “one-size-fits-all” approach (Merker et al., 2020). Conventional antibiotic therapy comprises either a single dose or a combination of two or more antibiotics. Limitations of this approach relate to issues such as misuse, overuse and underuse of antibiotics. These increased risk of adverse effects and toxicities, also reducing the efficacy of antibiotics (Ahmed et al., 2024a; Wawruch et al., 2002).
Precision Medicine helps to make customized and informed medical decisions, tailoring therapies by considering patients’ genetic makeup, immune response, specific infection, and socio-environmental and lifestyle factors. Precision medicine affirms the belief that every patient has different demands rather than a “one-size-fits-all” approach (Naithani et al., 2021). Such informed therapies allow for better treatment outcomes by selecting the most appropriate antibiotics, quick modifications of antibiotic regimens, and allowing for better antimicrobial stewardship. These ultimately prevent the development of AMR (Ahmed et al., 2024a; Watkins, 2022).
Pharmacogenomics
Precision medicine’s patient-centric approach allows us to closely monitor drug levels using therapeutic drug monitoring (TDM). This helps maintain the peak therapeutic efficacy of drugs while mitigating adverse effects and drug-related toxicities (Cusumano et al., 2020). Incorporating pharmacogenomic testing for single nucleotide polymorphisms (SNPs) and mutations brings out insights about patients’ responses towards the antimicrobial drugs prescribed to them. Thereby preventing unnecessary adverse drug reactions (ADRs) and toxicities promoting safe, effective, and conserved use of antimicrobial drugs (Daly, 2023). (Table 4) gives a detailed breakdown of genes, their Single nucleotide polymorphisms (SNPs) and the associated negatory effects (Hahn et al., 2016; Cirulli et al., 2019; Naidoo et al., 2017, 2018; Weiner et al., 2007, 2018; Andrews et al., 2010; Yee et al., 2013; Allegra et al., 2018a; Franke et al., 2011; Lancaster et al., 2012; Baietto et al., 2015; Allegra et al., 2018b; Chen et al., 2024; Estivill et al., 1998; Prezant et al., 1993; Gervasoni et al., 2013; Wang et al., 2012). SNPs that are related to various ADRs in persons carrying those mutations. These adverse effects include drug induced liver injuries (DILI), drug reactions with systemic eosinophilia (DRESS), nephrotoxicity, ototoxicity resulting in hearing loss, neutropenia, neurological side effects and immunologic adverse reactions (such as cutaneous adverse reactions due to polymorphisms in MHC Class I and II) a detailed breakdown is given in (Table 5) (Lucena et al., 2011; Stephens et al., 2013; Urban et al., 2017; Konvinse et al., 2019; Yang et al., 2017). An in-depth review of the pharmacogenomics of antibiotics (Stocco et al., 2020). Pharmacogenomic interpretation and screening for such polymorphisms will be of immense clinical importance; further research to prove such SNPs as biomarkers are required.
Table. Pharmacogenomic variants influencing antibiotic response and toxicities. (See the original article for the full table.)
Table. Antibiotics’ adverse drug reactions association with MHC Class I and II polymorphisms; DILI- Drug Induced Liver Injury. (See the original article for the full table.)
Metabolomics
Carbapenem-resistant Acinetobacter baumannii (CRAB) strains are prevalent worldwide and a significant threat to public health. Orthogonal Partial Least- Squares discriminant analysis (OPLS-DA) identified key biomarkers distinguishing Carbapenem-resistant Acinetobacter baumannii (CRAB) and Carbapenem-sensitive A. baumannii (CSAB). A total of 16 differential metabolites, including AMP, guanine, glutamine, fumarate, succinic acid, and α-ketoglutarate, were detected. Among these, eight metabolites were downregulated in CRAB, with six associated with the tricarboxylic acid (TCA) cycle and purine metabolism pathways (Li et al., 2024). An interesting example of discovering a metabolite-based antibiotic adjuvant by comparing the metabolic profiles of Gentamicin-sensitive Salmonella Choleraesuis (SCH-S) and gentamicin-resistant Salmonella Choleraesuis (SCH-R). Remarkably, D-ribose was the most suppressed metabolite in SCH-R and enhanced the efficacy of gentamicin against SCH-R and clinical multidrug-resistant strains (Zhou et al., 2022). Glucose and alanine are prominent biomarkers whose abundances are significantly reduced in kanamycin-resistant Edwardsiella tarda (Peng et al., 2015).
The potential mechanisms of utilizing gas chromatography-mass spectrometry (GC-MS) based metabolomics approaches are explored to profile the metabolomes of Edwardsiella tarda in the presence or absence of serum stress. They identified exogenous succinate as promoting the TCA cycle and increasing serum resistance, while TCA cycle inhibitors (bromopyruvate and propanedioic acid) that inhibit the TCA cycle attenuated serum resistance (Cheng et al., 2017). The metabolic profiles of clinically isolated multidrug-resistant and susceptible Escherichia coli, identifying glutamine as a potential biomarker that is suppressed in drug-resistant strains (Zhao et al., 2021). The differential metabolomes of S. agalactiae evades serum-mediated killing. Through bioinformatics analysis, decreased malic acid and increased adenosine are identified as the most crucial biomarker. The findings reveal that S. agalactiae utilizes a metabolic trick to respond to plasma killing due to serum resistance (Wang et al., 2016). To determine resistance profiles of A. baumannii (ATCC strain), 26 clinical isolates were screened against ciprofloxacin, colistin, cefixime, gentamicin, and co-amoxiclav. Malleobactin, Endophenazine, pyochelin, and L-lysine were significantly associated with ciprofloxacin resistance while Cefixime resistance is associated with L-serine and cytidine (Ramzan et al., 2025). A total of 40 metabolites were differentiated between ciprofloxacin. Susceptible and resistant isolates of Klebsiella oxytoca. Univariate receiver operating characteristic (ROC) curve analyses revealed that six of these metabolites, glycerol-3-phosphate, O-phosphoethanolamine, asparagine dehydrate, maleimide, tyrosine, and alanine, have a crucial role in distinguishing susceptible from resistant isolates (AUC>0.84) contributing to antimicrobial resistance. The identified metabolites belong to central carbon metabolism, arginine and proline metabolism; alanine, aspartate, and glutamate metabolism; and pyruvate metabolism (Ahmed et al., 2024b).
Proteomics
Whole-genome sequencing and proteome analysis of Escherichia coli, have decoded the dominant Antimicrobial Resistance Genes blaCTX-M-15, blaCMY-42, blaNDM-5, and aadA (Mat Ghani et al., 2025) and blaTEM-1B, blaOXA-232, blaNDM-1, rmtB, and rmtC were dominant in Klebsiella pneumoniae. In contrast, Pseudomonas aeruginosa and Acinetobacter baumannii harbored blaVEB, blaVIM-2, aph(3’), strA/B, blaOXA-23, aph(3′) variants, and amrA, respectively (Mehrotra et al., 2023). Acinetobacter baumannii strains revealed the role of blaOXA-23 and blaOXA-66 genes in carbapenem resistance. Through 16S rRNA gene sequence analysis and species-specific PCR targeting, the blaOXA51-like gene has been identified. Comparative genome analysis revealed blaOXA-66 as the most dominant variant of blaOXA-51-like gene and a widespread distribution of blaOXA-23 gene (Mat Ghani et al., 2025).
Multidrug-resistant E. coli proteome under antimicrobial pressure highlights a significant role for chromosomally encoded genes. Several proteins with altered abundance in response to ampicillin, cefotaxime, and imipenem, compared to untreated controls, have been identified. These include stress-related proteins such as ecotin (Eco) and methionine-R-sulfoxide reductase (MsrC) and detoxification proteins like SodA (ampicillin and cefotaxime), OsmC, GrxC, GrxD (cefotaxime), OxyR (imipenem), and PspE (cefotaxime and imipenem). Cold shock proteins (CspE, CspA) were elevated in cefotaxime, imipenem, and ampicillin-treated groups. Additionally, β-lactamase CTX-M-15 was significantly upregulated under cefotaxime exposure and TEM-1 under imipenem, but neither in response to ampicillin (Margalit et al., 2022). These findings partially differ from Møller et al. and can be attributed to differences in β-lactamase variants, antibiotic concentrations, and plasmid content (Møller et al., 2017). Bacteroides fragilis can be classified into division I (cfiA negative - chromosomal carbapenemase gene negative) and division II (cfiA positive- chromosomal carbapenemase gene positive) isolates. 14.9% proportion of cfiA-positive B. fragilis among blood culture isolates. Division II (cfiA positive) B. fragilis is more resistant to β-lactam antibiotics than division I (cfiA negative), making cfiA a valuable biomarker for antimicrobial therapy. Empiric treatment for Division II isolates should avoid carbapenems and co-amoxiclav (Jeverica et al., 2019).
An easy and rapid protocol for detecting KPC (Klebsiella pneumoniae carbapenemase) by MALDI-TOF MS is developed from the colony, and positive blood culture of Klebsiella pneumoniae and Escherichia coli. Statistical results showed 100% sensitivity, CI 95%: [94.0%; 100%] and 100% specificity, CI 95%: [94.6%; 100%], indicating a promising test with a high discriminative power. This approach offers a cost-effective and clinically impactful tool for early detection of KPC-2, supporting timely and targeted antibiotic stewardship in Enterobacterales infections (Figueroa-Espinosa et al., 2019). The “MALDIxin” test, a MALDI-TOF MS-based diagnostic that identifies polymyxin resistance in intact Escherichia coli within 15 minutes. The assay detects pETN-modified lipid A and distinguishes between chromosomal and plasmid-encoded resistance mechanisms. MALDIxin test accurately identified all mcr-1 producers in a blinded panel of carbapenemase-producing E. coli (Dortet et al., 2018).
Transcriptomics
There are various transcriptome biomarkers which actively promote Pseudomonas aeruginosa resistance to several drug classes. The algX gene, which stimulates alginate production, most likely enhances the protection for fluoroquinolones like ciprofloxacin by facilitating the formation of biofilms. In addition, the expression levels of the putative proteins like PA14_32290, PA14_48950, and PA14_59390 also indicated resistance against antibiotics. Furthermore, resistant strains showed an increased expression of the opdP gene, which codes for a glycine-glutamate dipeptide porin, and yedZ (PA14_62100), a sulfide oxidase subunit. One important factor in the development of multidrug resistance, particularly ciprofloxacin resistance, was the sensor kinase gene cbrA (Khaledi et al., 2016). The ampC gene showed a strong connection with ceftazidime resistance for β-lactam antibiotics such as ceftazidime and meropenem, with higher minimum inhibitory concentrations (MICs) correlating to greater expression levels (Libbrecht and Noble, 2015; Sundaramurthy and Eghbalnia, 2015).
The oprD gene, which codes for a carbapenem entry porin, downregulated in meropenem-resistant strains. The relevance of this downregulation in resistance was validated by protein studies and nonsense mutations, even though it did not reach statistical significance by AUC. In addition, the meropenem resistance pattern was influenced by the increased expression of genes such gbuA (a guanidinobutyrase involved in the arginine dehydrogenase pathway), cc4 (encoding the diheme protein cytochrome c4), and PA14_46110 (a putative sodium-solute symporter). When combining these indicators, it provides helpful targets for clinical testing and aid in the prediction of resistance phenotypes (Köhler et al., 1999).
Role of antimicrobial stewardship programs and infection control measures
AMR is a significant threat to public health, driven by several key issues. These include inappropriate and overuse of antibiotics in humans and agriculture, and poor infection control and management. This is further exacerbated by the inaccessibility of clean drinking water and proper sanitation, increased travel and globalization, and the slow development of novel or improved antimicrobial drugs (Mukherjee, 2024). The management of antimicrobial resistance now requires antimicrobial stewardship, which seeks to maximize antibiotic use through coordinated actions across healthcare settings, especially considering the slow development of new antibiotics (Ha et al., 2019). Studies reveal that integrating antimicrobial stewardship programs (ASPs) with infection prevention and control improves the efficacy of both approaches, as evidenced by notable decreases in infections, including Clostridium difficile infections, brought about by these coordinated initiatives (Knobloch et al., 2021). Moreover, in 2019, ICMR published the second version of its guidelines on using antibiotics in common syndromes, which includes updated information on how to treat skin infections, soft tissues, central nervous system, and bones and joints (Sandeep et al., 2020). So that ASPs are necessary for optimizing antibiotic use, improving patient safety, and lowering AMR (Ponto, 2010).
Antimicrobial stewardship methods can be applied in several ways:
Educating and screening of patients
Before prescribing antibiotics, screening and interacting with patients can help to reduce needless antibiotic use in healthcare settings. This can be of help to establish whether antibiotics are truly needed in a particular case. The Centers for Disease Control and Prevention have released a useful checklist to guide the healthcare facilities in more efficiently implementing the practice of screening patients for antibiotics (Sanchez, 2016).
Policy update
Updating hospital policy regarding antimicrobial stewardship initiatives is one of the most effective ways to enhance patient care and reduce needless medication use (Walia et al., 2019).
Limiting the use of antibiotics as a prevention strategy
The primary aim of antibiotics is to treat infections, not to prevent. However, there are some circumstances where antibiotics can be used for prophylaxis. Because of spread of AMR in hospitals, many institutions have begun to use antibiotics as a last resort rather than a first line of defense because there are other general prophylaxis such as hand hygiene which can help stop infections even before they start (Andersen, 2019).
Centers for Disease Control and Prevention (CDC) has list of steps that should be followed by healthcare professionals to ensure proper hand hygiene: Ensure that hand hygiene supplies are always available to all healthcare professionals. Antibacterial soap or 2% chlorhexidine gluconate solution is also a better option for proper hand hygiene. However, any ethanol-based hand rub (70% v/v) will also be equally effective (Lemmen and Lewalter, 2018).
Studies have shown that antimicrobial stewardship interventions in outpatient settings, particularly those involving pharmacist-led actions based on microbiology culture reports, yield significant clinical benefits. In a study by Wattengel et al. (2020), acceptance of pharmacist recommendations was associated with markedly lower rates of 30-day treatment failure (5% vs 28%) and 30-day hospital admission (0.7% vs 11%) compared with cases where the interventions were rejected.
De-escalation/modification
Modify empiric broad spectrum antibiotics depending on culture and antimicrobial susceptibility reports and patient status. Avoid double or redundant gram negative or anaerobic coverage - Discontinue antibiotics if a non-infectious mimic identified - De-escalate combination therapy to a single agent (Aggarwal et al., 2019).
Monitoring the path of every medication
Errors are expected whenever a drug is given to the patients. So, it is very crucial to track the path of every medication from the time it is prescribed until it is given to the patient. Maintaining records of medicine orders and administration is very crucial for tracking the path of medication order (Bankar et al., 2022).
Staff education
Limiting the use of antibiotics is only one component of effective antimicrobial stewardship. But it also includes giving training to staff on alternative treatment methods such as the use of gloves and hand sanitizer to prevent the spread of infections. In addition, it involves educating staffs about how infections are spread generally (Pereira et al., 2017).
By implementing these methods, infections can be reduced which will reduce the overall requirement of medicines.
CC BY 4.0. "Current status of antimicrobial resistance in Indian healthcare system: combating antimicrobial resistance with precision medicine" by Shinde A, Mohan A, Bulusu VM et al., Frontiers in antibiotics (2026). https://doi.org/10.3389/frabi.2026.1632790. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Peer-reviewed and open access; full text from PubMed Central (PMC12891089). Headings and layout adapted for reading; figures and tables are in the original.